Constellation Acquisition Corp I

OTCQB:CSTUF USA Shell Companies
Market Cap
$109.99K
Market Cap Rank
#38394 Global
#12492 in USA
Share Price
$11.42
Change (1 day)
+0.00%
52-Week Range
$11.42 - $11.42
All Time High
$11.42
About

Constellation Acquisition Corp I does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Constellation Acquisition Corp I (CSTUF) - Net Assets

Latest net assets as of September 2025: $-21.16 Million USD

Based on the latest financial reports, Constellation Acquisition Corp I (CSTUF) has net assets worth $-21.16 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($873.24K) and total liabilities ($22.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-21.16 Million
% of Total Assets -2423.34%
Annual Growth Rate 340.98%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 572830.32

Constellation Acquisition Corp I - Net Assets Trend (2020–2024)

This chart illustrates how Constellation Acquisition Corp I's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Constellation Acquisition Corp I (2020–2024)

The table below shows the annual net assets of Constellation Acquisition Corp I from 2020 to 2024.

Year Net Assets Change
2024-09-30 $8.27 Million -74.32%
2023-09-30 $32.19 Million -89.34%
2022-09-30 $302.03 Million +4.45%
2021-09-30 $289.16 Million +1322841.90%
2020-09-30 $21.86K --

Equity Component Analysis

This analysis shows how different components contribute to Constellation Acquisition Corp I's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1985493600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (September 2024)

Component Amount Percentage
Other Components $28.12 Million 340.25%
Total Equity $8.27 Million 100.00%

Constellation Acquisition Corp I Competitors by Market Cap

The table below lists competitors of Constellation Acquisition Corp I ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Constellation Acquisition Corp I's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 32,185,483 to 8,265,707, a change of -23,919,776 (-74.3%).
  • Net loss of 248,243 reduced equity.
  • Share repurchases of 23,671,533 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-248.24K -3.0%
Share Repurchases $23.67 Million -286.38%
Total Change $- -74.32%

Book Value vs Market Value Analysis

This analysis compares Constellation Acquisition Corp I's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 13.98x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 20703.55x to 13.98x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2020-09-30 $0.00 $11.42 x
2021-09-30 $7.46 $11.42 x
2022-09-30 $7.79 $11.42 x
2023-09-30 $2.63 $11.42 x
2024-09-30 $0.82 $11.42 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Constellation Acquisition Corp I utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -3.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 3.41x
  • Recent ROE (-3.00%) is below the historical average (1.39%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2021 5.44% 0.00% 0.00x 1.07x $-13.19 Million
2022 4.26% 0.00% 0.00x 1.04x $-17.33 Million
2023 -1.12% 0.00% 0.00x 1.55x $-3.58 Million
2024 -3.00% 0.00% 0.00x 3.41x $-1.07 Million

Industry Comparison

This section compares Constellation Acquisition Corp I's net assets metrics with peer companies in the Shell Companies industry.

Industry Context

  • Industry: Shell Companies
  • Average net assets among peers: $36,677,338
  • Average return on equity (ROE) among peers: -64.57%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Constellation Acquisition Corp I (CSTUF) $-21.16 Million 5.44% N/A $314.12K
Artius II Acquisition Inc. Class A Ordinary Shares (AACB) $-60.27K 0.00% 0.00x $198.37 Million
Artius II Acquisition Inc. Units (AACBU) $-60.27K 0.00% 0.00x $205.28 Million
Ares Acquisition Corporation II (AACT-UN) $931.34 Million 0.00% 0.08x $399.77 Million
AA Mission Acquisition Corp. (AAM-UN) $-559.90 Million 0.00% 0.00x $349.76 Million
Global Acquisitions Corporation (AASP) $3.80 Million -5.26% 0.34x $15.42 Million
ABV Consulting Inc (ABVN) $8.75K -623.31% 2.50x $461.96K
Atlantic Coastal Acquisition Corp II (ACAB) $-8.52 Million 0.00% 0.00x $2.44 Million
Annabidiol Corp (ACBD) $-501.57K 0.00% 0.00x $13.62K
ACRO Biomedical Co Ltd (ACBM) $685.87K -17.12% 0.46x $30.04K
Huaizhong Health Group Inc (ADAD) $-19.47K 0.00% 0.00x $3.15K